We report a case of tumor regression of multiple bone metastases from breast carcinoma after administration of strontium-89 chloride. This case suggests that strontium-89 chloride can not only relieve bone metastases pain not responsive to analgesics, but may also have a tumoricidal effect on bone metastases.
Introduction
Bone metastasis occurs in approximately 80% of patients with advanced breast cancer. Twenty to 85% of all cancer patients develop bone metastases during the clinical course, regardless of cancer type; 65-75% of these suffer from intolerable pain (1, 2) . To relieve bone pain, opioid analgesics and external radiotherapy have been used. However, controlling pain from multiple bone metastases is often difficult. Recently, strontium-89 chloride ( 89 SrCl 2 ) has been used as a palliative therapeutic option to relieve pain from bone metastases, even with multiple bone lesions (3, 4) . Its usefulness in relieving pain in patients with multiple bone metastases has been established, but few reports have described its tumoricidal effect on bone metastases (5) . We herein report a case of tumor regression of multiple bone metastases from breast cancer after administration of 89 SrCl 2 .
Case report
In September 2008, a 37-year-old woman underwent surgery for breast cancer in our institution. The postoperative clinical stage was T2N0M0. She underwent postoperative chemotherapy and endocrine therapy. In January 2009, multiple osteoblastic bone tumors, which had been causing severe back pain, were found on contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). Bone lesions were found in the whole spine, but as she complained of severe back pain, 40 Gy external radiotherapy was given from the 5th to the 9th thoracic vertebrae. After external radiotherapy, systemic chemotherapy was continued. In August 2010, multiple liver metastases were found on contrast-enhanced CT and the patient suffered from severe left hip pain. A bone scan showed increased uptake of Tc-99m hydroxymethylene diphosphonate (HMDP) in an area consistent with the left iliac bone. After 40Gy external radiotherapy of the left iliac bone, systemic chemotherapy was resumed. Despite continuing treatment, the multiple bone metastases and liver metastases increased in size. Serum carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) were increased. Bone scan showed multiple uptake of Tc-99m HMDP consistent with multiple bone metastases (Fig. 1a) , and on contrast-enhanced CT, the right 9th rib was destroyed by a huge bone tumor (Fig. 1b) . The multiple bone metastases were more progressive in size than the liver metastases and the severe pain could not be controlled with the use of opioid analgesics. After written informed consent was obtained, 89 SrCl 2 therapy was planned in order to control the pain.
In Five months after the 89 SrCl 2 injection, a bone scan showed decreased uptake of Tc-99m HMDP consistent with multiple bone lesions in regression (Fig. 2a) , and contrast-enhanced CT revealed bone tumor regression of the right 9th rib (Fig. 2b) . In consistence with the shrinking of multiple bone metastases, the CEA and CA 15-3 levels decreased (Fig. 3) . However, as the patient did not receive any systemic chemotherapy during this period, the liver metastases increased in size (Fig. 2b) . In May 2012, pain control was satisfactory, but a second injection of 89 SrCl 2 was administered at the request of the patient, because lower back pain from bone metastases remained. One month after the 89 SrCl 2 injection, transcatheter hepatic arterial chemotherapeutic infusion (TAI) was conducted for multiple liver metastases. After the second 89 SrCl 2 injection and TAI, the multiple bone metastases and liver metastases were well controlled. Currently, the patient is being treated on an outpatient basis without progression of symptoms.
Discussion
Metastatic bone tumor is a common and severe complication in advanced disease. It develops in up to 70% of patients with prostatic cancer and breast cancer, and in up to 30% with cancers of the lung, bladder, and thyroid (6) . The major complications associated with bone involvement are severe pain, spinal cord compression, and pathological fractures, all of which restrict mobility and sleep, greatly reducing the patient's quality of life.
To relieve bone pain, analgesia and external radiotherapy have been used. However, in patients with widespread painful bone involvement it is often difficult to control pain from multiple bone metastases. In 2007, 89 SrCl 2 (Metastron) was approved as a commercially available new drug for the treatment of multiple bone metastases in Japan. 89 SrCl 2 reaches metastatic bone sites throughout the whole body when administered intravenously as a single dose, and is therefore often employed to treat multiple bone metastases. 89 SrCl 2 is effective in providing pain relief with response rates of between 58% and 82% in patients with prostatic cancer or breast cancer bone metastasis (7, 8) . 89 SrCl 2 has been used as a palliative therapeutic option to relieve pain from multiple bone metastases. Its usefulness in relieving pain in patients with multiple bone metastases has been established, but few reports have described its tumoricidal effect on bone metastases (5).
89
SrCl 2 behaves like calcium; it is incorporated into the osteoid matrix adjacent to metastatic cells and emits b-rays. Autoradiography has revealed that the radiation dose absorbed by a metastatic tumor from 89 SrCl 2 is 1.3-64Gy (mean 18 AE 16Gy) (9) . This fact suggests that 89 SrCl 2 may have a sufficient therapeutic dose to have an anti-cancer effect depending on the site of the lesion. Turner et al. reported that a decrease of >50% in serum prostate-specific antigen was observed in 37% of patients with hormone-refractory prostate cancer after treatment with 89 SrCl 2 (10) . Furthermore, many patients show a reduced intensity of hot spots on bone scan compared with pretreatment images (5,6). These reports suggest a possible tumoricidal effect from 89 SrCl 2 . In our case, too, a huge bone tumor of the 9th rib regressed, and a bone scan showed a reduction of hot spots after administration of 89 SrCl 2 . We assume that anti-cancer effects of 89 SrCl 2 might have contributed to tumor regression and pain relief. In the present case, serum CEA and CA 15-3 levels decreased after administration of 89 SrCl 2 , while multiple liver metastases increased. This fact, too, suggests a possible tumoricidal action.
In conclusion, 89 SrCl 2 is not only useful as a palliative therapeutic option to relieve pain from multiple bone metastases, but also has a possible tumoricidal effect on bone metastases. However, the number of reported cases is still too small to suggest an anti-cancer effect with 89 SrCl 2 . Therefore, cases of regression of bone metastases after treatment with 89 SrCl 2 should be accumulated in the literature. Further studies are needed to address the questions of what dose and schedule to use, and which patients will respond.
